Functional autoantibodies against serpin E2 in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 62, Issue 1, 2010, Pages 93-104

  Maciejewska Rodrigues, H ^a   Al Shamisi, M ^a,b   Hemmatazad, H ^a   Ospelt, C ^a   Bouton, M C ^c   Jager D ^d   Cope, A P ^e   Charles, P ^e   Plant, D ^f   Distler, J H W ^g   Gay, R E ^a   Michel, B A ^a   Knuth, A ^a   Neidhart, M ^a   Gay, S ^a   Jungel A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; SERINE PROTEINASE INHIBITOR; SERPIN E2; UNCLASSIFIED DRUG; UROKINASE;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY ISOLATION; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JOINT DESTRUCTION; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOARTHRITIS; RECOMBINANT PROTEINS; SERPINS; SPONDYLITIS, ANKYLOSING; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 74849083742     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25038     Document Type: Article

References (49)

1. Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol 1992;31:365-8.
2. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914-7.
3. Halldorsdottir HD, Jonsson T, Thorsteinsson J, Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000;59:149-51.
4. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
5. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003;42:939-46.
6. Vaughan JH. Rheumatoid factors and their biological significance. Summary. Ann N Y Acad Sci 1969;168:204-7.
7. Walker DJ, Pound JD, Griffiths ID, Powell RJ. Rheumatoid factor tests in the diagnosis and prediction of rheumatoid arthritis. Ann Rheum Dis 1986;45:684-90.
8. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
9. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
10. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
11. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.
12. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvist SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002-8.
13. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008;58:1293-8.
14. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008;67:1557-61.
15. Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006;36:2250-63.
16. Gioud M, Meghlaoui A, Costa O, Monier JC. Antibodies to native type I and II collagens detected by an enzyme linked immunosorbent assay (ELISA) in rheumatoid arthritis and systemic lupus erythematosus. Coll Relat Res 1982;2:557-64.
17. Polgar A, Falus A, Koo E, Ujfalussy I, Sesztak M, Szuts I, et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford) 2003;42:522-7.
18. Ukaji F, Kitajima I, Kubo T, Shimizu C, Nakajima T, Maruyama I. Serum samples of patients with rheumatoid arthritis contain a specific autoantibody to "denatured" aldolase A in the osteoblastlike cell line, MG-63. Ann Rheum Dis 1999;58:169-74.
19. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7: R1421-9.
20. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application [review]. J Rheumatol 2008;35:1245.
21. Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002;127:379-85.
22. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 1998;95:6919-23.
23. Skoldberg F, Ronnblom L, Thornemo M, Lindahl A, Bird PI, Rorsman F, et al. Identification of AHNAK as a novel autoantigen in systemic lupus erythematosus. Biochem Biophys Res Commun 2002;291:951-8.
24. Lim Y, Lee DY, Lee S, Park SY, Kim J, Cho B, et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun 2002;295:119-24.
25. Tureci O, Usener D, Schneider S, Sahin U. Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 2005;109:137-54.
26. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. Salabe G, Corvo L, Lotz H. Purification of anti-thyroglobulin IgG from human serum. Clin Chem Lab Med 2000;38:597-602.
29. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1468-76.
30. Stevens P, Scott RW, Shatzen EM. Recombinant human protease nexin-1 prevents articular cartilage-degradation in the rabbit. Agents Actions Suppl 1993;39:173-7.
31. Ditzel HJ, Masaki Y, Nielsen H, Farnaes L, Burton DR. Cloning and expression of a novel human antibody-antigen pair associated with Felty's syndrome. Proc Natl Acad Sci U S A 2000;97:9234-9.
32. 2 in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease. J Clin Periodontol 2006;33:605-11.
33. Stenman M, Ainola M, Valmu L, Bjartell A, Ma G, Stenman UH, et al. Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue. Am J Pathol 2005;167:1119-24.
34. Judex MO, Mueller BM. Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 2005;166:645-7.
35. Mishiro T, Nakano S, Takahara S, Miki M, Nakamura Y, Yasuoka S, et al. Relationship between cathepsin B and thrombin in rheumatoid arthritis. J Rheumatol 2004;31:1265-73.
36. Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997;56:550-7.
37. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type IIinduced arthritis. Am J Pathol 2005;166:783-92.
38. Fenton JW II, Ofosu FA, Brezniak DV, Hassouna HI. Thrombin and antithrombotics. Semin Thromb Hemost 1998;24:87-91.
39. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-70.
40. Guiducci S, Del Rosso A, Cinelli M, Margheri F, D'Alessio S, Fibbi G, et al. Rheumatoid synovial fibroblasts constitutively express the fibrinolytic pattern of invasive tumor-like cells. Clin Exp Rheumatol 2005;23:364-72.
41. Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. J Biol Chem 1993;268:3720-7.
42. Mbebi C, Hantai D, Jandrot-Perrus M, Doyennette MA, Verdiere-Sahuque M. Protease nexin I expression is up-regulated in human skeletal muscle by injury-related factors. J Cell Physiol 1999;179:305-14.
43. Zer C, Sachs G, Shin JM. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-α signaling. Physiol Genomics 2007;31:343-51.
44. Rajashekhar G, Grow M, Willuweit A, Patterson CE, Clauss M. Divergent and convergent effects on gene expression and function in acute versus chronic endothelial activation. Physiol Genomics 2007;31:104-13.
45. Mansilla S, Boulaftali Y, Venisse L, Arocas V, Meilhac O, Michel JB, et al. Macrophages and platelets are the major source of protease nexin-1 in human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2008;28:1844-50.
46. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci U S A 1986;83:996-1000.
47. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1367-71.
48. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80.
49. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [review]. Arthritis Rheum 2002;46:862-73.